ABSTRACT
BACKGROUND: Hypomagnesaemia is present in 40-50% of children with autosomal dominant renal cysts and diabetes syndrome (RCAD). On the contrary, the prevalence of hypomagnesaemia in children with autosomal dominant polycystic kidney disease (ADPKD) has never been examined. We aimed to investigate whether hypomagnesaemia is present in children with polycystic kidney diseases. METHODS: Children with cystic kidney diseases were investigated in a cross-sectional study. Serum concentrations of magnesium (S-Mg) and fractional excretion of magnesium (FE-Mg) were tested. Fifty-four children with ADPKD ( n = 26), autosomal recessive polycystic kidney disease (ARPKD) ( n = 16) and RCAD ( n = 12) with median age of 11.2 (0.6-18.6) years were investigated. RESULTS: Hypomagnesaemia (S-Mg < 0.7 mmol/L) was detected in none of the children with ADPKD/ARPKD and in eight children (67%) with RCAD. Median S-Mg in children with ADPKD/ARPKD was significantly higher than in children with RCAD (0.89 vs. 0.65 mmol/L, P < 0.01). The FE-Mg was increased in 23% of patients with ADPKD/ARPKD (all had chronic kidney disease stages 2-4) and in 63% of patients with RCAD, where it significantly correlated with estimated glomerular filtration rate (r = -0.87, P < 0.01). CONCLUSIONS: Hypomagnesaemia is absent in children with ADPKD or ARPKD and could serve as a marker for differential diagnostics between ADPKD, ARPKD and RCAD in children with cystic kidney diseases of unknown origin where molecular genetic testing is lacking. However, while hypomagnesaemia, in the absence of diuretics, appears to rule out ADPKD and ARPKD, normomagnesaemia does not rule out RCAD at least in those aged <3 years.
Subject(s)
Hypercalciuria/epidemiology , Magnesium/blood , Nephrocalcinosis/epidemiology , Polycystic Kidney, Autosomal Dominant/epidemiology , Renal Tubular Transport, Inborn Errors/epidemiology , Adolescent , Central Nervous System Diseases/blood , Central Nervous System Diseases/diagnosis , Central Nervous System Diseases/epidemiology , Child , Child, Preschool , Cross-Sectional Studies , Dental Enamel/abnormalities , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/epidemiology , Diagnosis, Differential , Female , Humans , Hypercalciuria/blood , Hypercalciuria/diagnosis , Infant , Infant, Newborn , Kidney Diseases, Cystic/blood , Kidney Diseases, Cystic/diagnosis , Kidney Diseases, Cystic/epidemiology , Male , Nephrocalcinosis/blood , Nephrocalcinosis/diagnosis , Polycystic Kidney, Autosomal Dominant/blood , Polycystic Kidney, Autosomal Dominant/diagnosis , Polycystic Kidney, Autosomal Recessive/blood , Polycystic Kidney, Autosomal Recessive/diagnosis , Polycystic Kidney, Autosomal Recessive/epidemiology , Prevalence , Renal Tubular Transport, Inborn Errors/blood , Renal Tubular Transport, Inborn Errors/diagnosisABSTRACT
Autosomal recessive polycystic kidney disease (ARPKD) is associated with progressive enlargement of the kidneys fuelled by the formation and expansion of fluid-filled cysts. The disease is congenital and children that do not succumb to it during the neonatal period will, by age 10 years, more often than not, require nephrectomy+renal replacement therapy for management of both pain and renal insufficiency. Since increasing cystic index (CI; percent of kidney occupied by cysts) drives both renal expansion and organ dysfunction, management of these patients, including decisions such as elective nephrectomy and prioritization on the transplant waitlist, could clearly benefit from serial determination of CI. So also, clinical trials in ARPKD evaluating the efficacy of novel drug candidates could benefit from serial determination of CI. Although ultrasound is currently the imaging modality of choice for diagnosis of ARPKD, its utilization for assessing disease progression is highly limited. Magnetic resonance imaging or computed tomography, although more reliable for determination of CI, are expensive, time-consuming and somewhat impractical in the pediatric population. Using a well-established mammalian model of ARPKD, we undertook a big data-like analysis of minimally- or non-invasive blood and urine biomarkers of renal injury/dysfunction to derive a family of equations for estimating CI. We then applied a signal averaging protocol to distill these equations to a single empirical formula for calculation of CI. Such a formula will eventually find use in identifying and monitoring patients at high risk for progressing to end-stage renal disease and aid in the conduct of clinical trials.
Subject(s)
Biomarkers , Polycystic Kidney, Autosomal Recessive/blood , Polycystic Kidney, Autosomal Recessive/urine , Renal Insufficiency/blood , Renal Insufficiency/urine , Animals , Biomarkers/blood , Biomarkers/urine , Blood Urea Nitrogen , Child , Creatinine/blood , Cystatin C/blood , Cysts/pathology , Hepatitis A Virus Cellular Receptor 1/blood , Humans , Interleukin-18/blood , Kidney/diagnostic imaging , Kidney/metabolism , Kidney/physiopathology , Kidney Transplantation , Lipocalin-2/blood , Magnetic Resonance Imaging , Mice , Polycystic Kidney, Autosomal Recessive/diagnostic imaging , Polycystic Kidney, Autosomal Recessive/pathology , Rats , Renal Insufficiency/pathology , Severity of Illness Index , UltrasonographySubject(s)
Cohort Studies , DNA Mutational Analysis/methods , Genetic Testing/methods , Mutation , Polycystic Kidney, Autosomal Recessive/genetics , Receptors, Cell Surface/genetics , Evaluation Studies as Topic , Female , Fetus/metabolism , Genetic Variation , Genotype , Humans , Phenotype , Polycystic Kidney, Autosomal Recessive/blood , Polymorphism, Single Nucleotide/genetics , Pregnancy , Receptors, Cell Surface/analysisABSTRACT
Rodent models of polycystic kidney disease (PKD) have provided valuable insight into the cellular changes associated with cystogenesis in humans. The present study characterizes the morphology of renal and extrarenal pathology of autosomal recessive PKD induced by the wpk gene in Wistar rats. In wpk(-/-) rats, proximal tubule and collecting duct cysts develop in utero and eventually consume the kidney. Increased apoptosis, mitosis, and extracellular tenascin deposition parallel cyst development. Extrarenal pathology occurs in the immune system (thymic and splenic hypoplasia) and central nervous system (CNS; hypoplasia to agenesis of the corpus callosum with severe hydrocephalus). Severity of hydrocephalus varied inversely with size of the corpus callosum. In wpk(-/-) rats, the corpus callosum exhibits relatively few axons that cross the midline. This CNS pathology is similar to that described in three human renal cystic syndromes: orofaciodigital, genitopatellar, and cerebrorenal-digital syndromes. Collecting duct and ventricular ependymal cilia appear morphologically normal. To determine if rodent background strain and the presence of modifier genes affect severity of the disease, we crossed the Wistar-wpk rat with Brown Norway (BN) and Long Evan (LE) rats and found the degree of renal and cerebral pathology was diminished as evidenced by lower kidney weight as a percent of body weight and serum urea nitrogen concentration in cystic rats on LE or BN strains as well as less prominent cranial enlargement. Crosses with BN rats allowed us to localize the wpk gene on chromosome 5 very close to the D5Rat73 marker. The wpk gene lies within a chromosomal region known to harbor a PKD modifier locus. In summary, the types of renal and cerebral pathology seen in the Wistar wpk rat are a unique combination seen only in this rodent model.
Subject(s)
Agenesis of Corpus Callosum , Corpus Callosum/pathology , Disease Models, Animal , Kidney/pathology , Polycystic Kidney, Autosomal Recessive/genetics , Polycystic Kidney, Autosomal Recessive/pathology , Analysis of Variance , Animals , Animals, Genetically Modified , Blood Urea Nitrogen , Female , Hydrocephalus/blood , Hydrocephalus/genetics , Hydrocephalus/pathology , Male , Polycystic Kidney, Autosomal Recessive/blood , Rats , Rats, Long-Evans , Rats, Wistar , Species Specificity , Statistics, Nonparametric , SyndromeABSTRACT
A novel hemoglobin variant was detected by electrospray ionization mass spectrometry. Hb Zurich-Hottingen is characterized by an Asn --> Ser replacement in the alpha-chain at position 9 as confirmed by DNA analysis. This hemoglobin variant is silent in isoelectric focusing, reversed-phase chromatography, and cation-exchange chromatography. The mutant alpha-chain was detectable only with electrospray mass spectrometry by its mass shift of -27 Da. The carrier was found to be heterozygous for the new hemoglobin variant. These results illustrate the power of ESI mass spectrometry for hemoglobin analysis.
Subject(s)
Hemoglobins, Abnormal/chemistry , Hemoglobins, Abnormal/genetics , Spectrometry, Mass, Electrospray Ionization , Child , Chromatography, High Pressure Liquid , DNA Mutational Analysis , Erythrocyte Indices/genetics , Genetic Carrier Screening , Hematocrit , Heterozygote , Humans , Hypersplenism/blood , Hypersplenism/complications , Liver Cirrhosis/blood , Liver Cirrhosis/complications , Male , Molecular Weight , Polycystic Kidney, Autosomal Recessive/blood , Polycystic Kidney, Autosomal Recessive/complications , Portugal/ethnology , Protein Subunits , Sequence Analysis, ProteinABSTRACT
The kidney function in a model of autosomal dominant polycystic kidney disease (PKD), the Han:SPRD rat, is dramatically improved by chronic ingestion of a solution of potassium citrate and citric acid (KCitr). This study investigated whether this treatment would also be beneficial in the pcy/pcy mouse, a model of autosomal recessive PKD. Starting at 1 month of age, male CD-1 pcy/pcy and normal CD-1 mice were provided with a solution of 55 mM K(3) citrate/67 mM citric acid or tap water to drink. The pcy/pcy mice on the KCitr solution failed to grow normally and showed elevated plasma urea levels when compared to water-drinking littermates. Growth of normal CD-1 mice was not affected by KCitr intake. The pcy/pcy mice were then provided with a more dilute solution of KCitr to drink: this resulted in greater kidney wet and dry weights and a higher kidney weight/body weight ratio, but no beneficial effects. We conclude that pcy/pcy mice cannot tolerate a high level of KCitr intake and that a lower level is of no benefit. Whether KCitr therapy would be helpful in patients with PKD is still an open question.
Subject(s)
Chelating Agents/therapeutic use , Citric Acid/therapeutic use , Diuretics/therapeutic use , Polycystic Kidney, Autosomal Recessive/drug therapy , Potassium Citrate/therapeutic use , Animals , Body Weight/drug effects , Disease Models, Animal , Female , Glomerular Filtration Rate/drug effects , Kidney/drug effects , Male , Mice , Mice, Inbred Strains , Organ Size/drug effects , Polycystic Kidney, Autosomal Recessive/blood , Urea/bloodABSTRACT
PURPOSE: To evaluate progressive US changes in the kidneys of patients with familial juvenile nephronophthisis (NPH), an autosomal recessive progressive kidney disease with polyuria, polydipsia, anemia and growth retardation. MATERIAL AND METHODS: The data from 29 US investigations of 5 boys and 2 girls comprised findings relating to kidney size, echogenicity of the kidney parenchyma, visualization of the corticomedullary junction, and the parameters of renal cysts. RESULTS: In the early stages of NPH, when the serum creatinine values were between 134 and 370 micromol/l, the corticomedullary differentiation was weak in 6 patients, the echogenicity of the kidney parenchyma was equal to or greater than that of the liver in 5 patients, and 6 patients had developed renal cysts. The findings became more intensive with the progression of NPH. The size of the kidneys remained normal in 4 patients. CONCLUSION: Renal US reveals characteristic changes already in the early stages of NPH and should therefore be an important part of the diagnostics of NPH because no specific diagnostic test is as yet available.